Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Actinium Pharmaceuticals (ATNM) Research & Development (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Research & Development for 6 consecutive years, with -$4.1 million as the latest value for Q4 2025.

  • Quarterly Research & Development changed N/A to -$4.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.7 million through Dec 2025, changed N/A year-over-year, with the annual reading at $21.1 million for FY2025, 29.69% down from the prior year.
  • Research & Development for Q4 2025 was -$4.1 million at Actinium Pharmaceuticals, down from $4.2 million in the prior quarter.
  • The five-year high for Research & Development was $11.6 million in Q3 2023, with the low at -$4.1 million in Q4 2025.
  • Average Research & Development over 5 years is $6.2 million, with a median of $6.6 million recorded in 2024.
  • The sharpest move saw Research & Development surged 137.69% in 2023, then tumbled 56.54% in 2025.
  • Over 5 years, Research & Development stood at $5.4 million in 2021, then soared by 35.4% to $7.3 million in 2022, then grew by 10.71% to $8.1 million in 2023, then increased by 20.4% to $9.8 million in 2024, then tumbled by 142.05% to -$4.1 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at -$4.1 million, $4.2 million, and $4.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.